Hence then, the article about intellia and regeneron present updated interim data from phase 1 study of crispr based ntla 2001 for the treatment of transthyretin attr amyloidosis demonstrating that deep serum ttr reductions remained durable after a single dose was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose )
Also on site :
- Suspect in deadly San Jose police shooting identified
- South Africa pushes for renewable energy investment
- Zelensky is ‘a man in a desperate position’ – Orban